Award for Lars Lannfelt, Who Paved the Way for the Alzheimer’s Drug “Lecanemab”
DZNE Abt fuer Presse; Oeffentlichkeitsarbeit
Swedish scientist receives “Hartwig Piepenbrock-DZNE Prize”
Bonn/Osnabrück (Germany), Stockholm (Sweden); June 26, 2025. This year’s “Hartwig Piepenbrock-DZNE Prize”, endowed with 60,000 euros, goes to Swedish medical scientist Lars Lannfelt for his pioneering contributions to the understanding of Alzheimer’s disease and to the development of the drug “Lecanemab”. This medicine, used to treat Alzheimer’s, the most common form of dementia, is the first disease-modifying drug of its kind in the...